AMELION: A Randomized, Double Blinded, Phase 2, Efficacy and Safety Study of Abituzumab (EMD 525797) in Combination With Cetuximab and FOLFIRI Versus Placebo in Combination With Cetuximab and FOLFIRI in First-line RAS Wild-type, Left-sided, Metastatic Colorectal Cancer Patients With High ανβ6 Integrin Expression.
The purpose of this study is to evaluate the safety and efficacy of the experimental drug abituzumab (EMD525797) in combination with cetuximab and FOLFIRI in RAS wild-type, left-sided, metastatic colorectal cancer patients with high ανβ6 integrin expression.
100 Clinical Results associated with SFJ Pharmaceuticals X, LTD.
0 Patents (Medical) associated with SFJ Pharmaceuticals X, LTD.
100 Deals associated with SFJ Pharmaceuticals X, LTD.
100 Translational Medicine associated with SFJ Pharmaceuticals X, LTD.